Literature DB >> 20422210

The ENETS and AJCC/UICC TNM classifications of the neuroendocrine tumors of the gastrointestinal tract and the pancreas: a statement.

Günter Klöppel, Guido Rindi, Aurel Perren, Paul Komminoth, David S Klimstra.   

Abstract

Entities:  

Mesh：

Year:  2010        PMID： 20422210     DOI： 10.1007/s00428-010-0924-6

Source DB:  PubMed          Journal:  Virchows Arch        ISSN： 0945-6317            Impact factor:   4.064


× No keyword cloud information.
  9 in total

1.  TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; A Couvelard; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

2.  Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set.

Authors:  David S Klimstra; Irvin R Modlin; N Volkan Adsay; Runjan Chetty; Vikram Deshpande; Mithat Gönen; Robert T Jensen; Mark Kidd; Matthew H Kulke; Ricardo V Lloyd; Cesar Moran; Steven F Moss; Kjell Oberg; Dermot O'Toole; Guido Rindi; Marie E Robert; Saul Suster; Laura H Tang; Chin-Yuan Tzen; Mary Kay Washington; Betram Wiedenmann; James Yao
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

3.  Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients.

Authors:  Aldo Scarpa; William Mantovani; Paola Capelli; Stefania Beghelli; Letizia Boninsegna; Rossella Bettini; Francesco Panzuto; Paolo Pederzoli; Gianfranco delle Fave; Massimo Falconi
Journal:  Mod Pathol       Date:  2010-03-19       Impact factor: 7.842

4.  Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution.

Authors:  Sara Ekeblad; Britt Skogseid; Kristina Dunder; Kjell Oberg; Barbro Eriksson
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

5.  Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors.

Authors:  Ulrich-Frank Pape; Henning Jann; Jacqueline Müller-Nordhorn; Angelina Bockelbrink; Uta Berndt; Stefan N Willich; Martin Koch; Christoph Röcken; Guido Rindi; Bertram Wiedenmann
Journal:  Cancer       Date:  2008-07-15       Impact factor: 6.860

6.  Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas.

Authors:  L Fischer; J Kleeff; I Esposito; U Hinz; A Zimmermann; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2008-05       Impact factor: 6.939

7.  Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors.

Authors:  Stefano La Rosa; Catherine Klersy; Silvia Uccella; Linda Dainese; Luca Albarello; Angelica Sonzogni; Claudio Doglioni; Carlo Capella; Enrico Solcia
Journal:  Hum Pathol       Date:  2008-08-20       Impact factor: 3.466

8.  WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors.

Authors:  Anja M Schmitt; Martin Anlauf; Valentin Rousson; Sonja Schmid; Andreas Kofler; Florian Riniker; Juliane Bauersfeld; Andre Barghorn; Nicole M Probst-Hensch; Holger Moch; Philipp U Heitz; Guenter Kloeppel; Paul Komminoth; Aurel Perren
Journal:  Am J Surg Pathol       Date:  2007-11       Impact factor: 6.394

9.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.

Authors:  G Rindi; G Klöppel; H Alhman; M Caplin; A Couvelard; W W de Herder; B Erikssson; A Falchetti; M Falconi; P Komminoth; M Körner; J M Lopes; A-M McNicol; O Nilsson; A Perren; A Scarpa; J-Y Scoazec; B Wiedenmann
Journal:  Virchows Arch       Date:  2006-09-12       Impact factor: 4.064
  9 in total
  61 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

Review 2.  Management of functional neuroendocrine tumors of the pancreas.

Authors:  Kjell Öberg
Journal:  Gland Surg       Date:  2018-02

3.  Short-term and long-term outcomes after robot-assisted versus laparoscopic distal pancreatectomy for pancreatic neuroendocrine tumors (pNETs): a multicenter comparative study.

Authors:  Sergio Alfieri; Giovanni Butturini; Ugo Boggi; Andrea Pietrabissa; Luca Morelli; Fabio Vistoli; Isacco Damoli; Andrea Peri; Claudio Fiorillo; Luigi Pugliese; Marco Ramera; Nelide De Lio; Gregorio Di Franco; Alessandro Esposito; Luca Landoni; Fausto Rosa; Roberta Menghi; Giovanni Battista Doglietto; Giuseppe Quero
Journal:  Langenbecks Arch Surg       Date:  2019-05-04       Impact factor: 3.445

Review 4.  Medical Therapy of Gastrointestinal Neuroendocrine Tumors.

Authors:  Kjell Öberg
Journal:  Visc Med       Date:  2017-09-18

Review 5.  [Pathology of neuroendocrine neoplasms].

Authors:  M Anlauf; P Gerlach; M Schott; A Raffel; M Krausch; W T Knoefel; M Pavel; G Klöppel
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

Review 6.  The pathological diagnosis of neuroendocrine tumors: common questions and tentative answers.

Authors:  Marco Volante; Luisella Righi; Alfredo Berruti; Guido Rindi; Mauro Papotti
Journal:  Virchows Arch       Date:  2011-02-23       Impact factor: 4.064

Review 7.  Pancreatic neuroendocrine tumors.

Authors:  Shailesh V Shrikhande; Bhawna Sirohi; Mahesh Goel; Savio G Barreto
Journal:  Indian J Gastroenterol       Date:  2012-10-03

8.  Pancreatic neuroendocrine tumors in MEN1 disease: a mono-centric longitudinal and prognostic study.

Authors:  S Chiloiro; F Lanza; A Bianchi; G Schinzari; M G Brizi; A Giampietro; V Rufini; F Inzani; A Giordano; G Rindi; A Pontecorvi; L De Marinis
Journal:  Endocrine       Date:  2017-05-31       Impact factor: 3.633

9.  Second-line chemotherapy for refractory small cell neuroendocrine carcinoma of the esophagus that relapsed after complete remission with irinotecan plus cisplatin therapy: Case report and review of the literature.

Authors:  Shinsuke Funakoshi; Akinori Hashiguchi; Kana Teramoto; Naoteru Miyata; Satoshi Kurita; Masayuki Adachi; Yasuo Hamamoto; Hajime Higuchi; Hiromasa Takaishi; Toshifumi Hibi
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

Review 10.  Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy.

Authors:  R J Hicks
Journal:  Cancer Imaging       Date:  2010-10-04       Impact factor: 3.909
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.